Bulevirtide (Myrcludex B)

About the Target

Bulevirtide (Myrcludex B) is a sodium-taurocholate co-transporting polypeptide (NTCP) receptor inhibitor with IC50 of ∼80 pM and inactivates NTCP function at concentrations far below those required to block bile salt transport. The mapped target for this entry is Sodium/taurocholate cotransporting polypeptide (NTCP) (SLC10A1). The mapped biology is best interpreted at pathway or interactome level, where the peptide is used to bias a response without assuming that every downstream change reflects exclusive engagement of one molecular species. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. In practical terms, it supports network-level interpretation of experiments that need a controlled but not oversimplified perturbation.

Research Context

In inhibitor studies, researchers generally relate exposure to suppression of the mapped pathway, then compare phenotypic readouts with orthogonal markers of target engagement or pathway compensation. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses.

• pair treatment with orthogonal pathway biomarkers whenever direct target engagement cannot be assumed
• use dose-response and time-course designs to connect early pathway shifts with later phenotypic outcomes
• frame conclusions at network level when more than one molecular node may contribute to the effect

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

For routine mechanistic work, the unmodified catalog format provides a consistent starting point for concentration-response studies, benchmark experiments, and orthogonal validation. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.